Scinai Immunotherapeutics (SCNI) Non-Current Debt (2018 - 2025)

Scinai Immunotherapeutics has disclosed Non-Current Debt across 8 years of filings, most recently posting $294000.0 for Q4 2025.

• Non-Current Debt for Q4 2025 came in at $294000.0, up 13.08% year-over-year; the trailing twelve-month figure through Dec 2025 was $294000.0 (up 13.08% YoY), and the FY2025 annual result was $294000.0, up 13.08% from the prior year.
• Non-Current Debt came in at $294000.0 for Q4 2025 at Scinai Immunotherapeutics, roughly flat from $293000.0 in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $64.2 billion in Q2 2021 to a low of $260000.0 in Q4 2024.
• The 5-year median for Non-Current Debt is $19.7 million (2024), against an average of $7.0 billion.
• Across the five-year window, Non-Current Debt slumped 99.98% in 2022 and surged 56.92% in 2023, its largest moves.
• Scinai Immunotherapeutics' Non-Current Debt stood at $27.2 million in 2021, then decreased by 26.07% to $20.1 million in 2022, then slipped by 3.56% to $19.4 million in 2023, then plunged by 98.66% to $260000.0 in 2024, then advanced by 13.08% to $294000.0 in 2025.
• The last three Non-Current Debt figures came in at $294000.0 (Q4 2025), $293000.0 (Q2 2025), and $260000.0 (Q4 2024), per Business Quant data.